
Rd Feldman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2337021/publications.pdf Version: 2024-02-01



PD FELDMAN

#	Article	IF	CITATIONS
1	Insulin-mediated vasodilation: impairment with increased blood pressure and body mass. Lancet, The, 1993, 342, 707-709.	6.3	142
2	Oxidant Stress Enhances Adenylyl Cyclase Activation. Circulation Research, 1995, 77, 710-717.	2.0	68
3	G Protein Alterations in Hypertension and Aging. Hypertension, 1995, 26, 725-732.	1.3	48
4	Moderate dietary salt restriction increases vascular and systemic insulin resistance. American Journal of Hypertension, 1999, 12, 643-647.	1.0	41
5	Deactivation of Vasodilator Responses by GRK2 Overexpression:A Mechanism or the Mechanism for Hypertension?. Molecular Pharmacology, 2002, 61, 707-709.	1.0	21
6	New insights into the regulation of cAMP synthesis beyond GPCR/G protein activation: Implications in cardiovascular regulation. Life Sciences, 2007, 81, 267-271.	2.0	20
7	Heart Disease in Women: Unappreciated Challenges, GPER as a New Target. International Journal of Molecular Sciences, 2016, 17, 760.	1.8	19
8	GPER-independent effects of estrogen in rat aortic vascular endothelial cells. Molecular and Cellular Endocrinology, 2015, 399, 60-68.	1.6	17
9	Quinapril treatment enhances vascular sensitivity to insulin. Journal of Hypertension, 2001, 19, 113-118.	0.3	15
10	Intraclass Differences Among Antihypertensive Drugs. Annual Review of Pharmacology and Toxicology, 2015, 55, 333-352.	4.2	14
11	Impact of spironolactone exposure on prostate cancer incidence amongst men with heart failure: A Pharmacoepidemiological study. British Journal of Clinical Pharmacology, 2021, 87, 1801-1813.	1.1	12
12	Vanadate stimulation of adenylyl cyclase: An index of tyrosine kinase vascular effects*. Clinical Pharmacology and Therapeutics, 1999, 66, 275-281.	2.3	10
13	Betaâ€adrenoceptor responsiveness in hypertension: effects of dietary NaCl intake British Journal of Clinical Pharmacology, 1990, 30, 55S-60S.	1.1	8
14	Obesity/Metabolic Syndrome Overview. , 2007, , 381-387.		1
15	Application of Hypertension Guidelines in the Elderly: Revisiting Where the Bridge to Nowhere Might Actually BeÂGoing. Canadian Journal of Cardiology, 2017, 33, 591-593.	0.8	1
16	Type 2 Diabetes and the Reduction of Cardiovascular Risk: Sorting Out the Actors and the Roles. Canadian Journal of Cardiology, 2018, 34, 532-535.	0.8	1
17	Primary Aldosteronism in Hypertension: More Than a Factoid. Canadian Journal of Cardiology, 2021, 37, 196-198.	0.8	1
18	The Rise and Fall of Hypertension Control in Canada: The Beginning of the End or the End of the Beginning?. Canadian Journal of Cardiology, 2021, 37, 679-682.	0.8	1

#	Article	IF	CITATIONS
19	Down the Rabbit Hole: Hypertension Guidelines, Goals and Gulfs Across the 49th Parallel. Canadian Journal of Cardiology, 2018, 34, 543-545.	0.8	0